Ticiana Aparecida Alves de Mira

Ticiana Aparecida Alves de Mira

Auto-generated profile, based on publicly available information

Ticiana Aparecida Alves de Mira

Department of Obstetrics and Gynecology, School of Medical Science, Universidade Estadual de Campinas

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2018 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
TMTiciana A.A. Mira
Ticiana A.A. Mira
MBMariana M. Buen
Mariana M. Buen
MBMurilo G. Borges
Murilo G. Borges
DYDaniela A. Yela
Daniela A. Yela
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto

1 December 2020 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
TMTiciana A.A. Mira
Ticiana A.A. Mira
DYDaniela A. Yela
Daniela A. Yela
SPSérgio Podgaec
Sérgio Podgaec
EBEdmund Chada Baracat
Edmund Chada Baracat
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto

1 November 2015 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
TMTiciana A.A. Mira
Ticiana A.A. Mira
PGPaulo C. Giraldo
Paulo C. Giraldo
DYDaniela A. Yela
Daniela A. Yela
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto

23 September 2019 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto
TMTiciana Aparecida Alves de Mira
Ticiana Aparecida Alves de Mira
DYDaniela Angerame Yela
Daniela Angerame Yela
CTCassia Raquel Teatin-Juliato
Cassia Raquel Teatin-Juliato
LBLuiz Gustavo Oliveira Brito
Luiz Gustavo Oliveira Brito
Objective To assess the efficacy of non-surgical treatment for adenomyosis. Data Sources A search was performed by two authors in the Pubmed, Scopus, and Scielo databases and in the grey literature from inception to March 2018, with no language restriction. Selection of Studies We have included prospective randomized studies for treating symptomatic women with adenomyosis (abnormal uterine bleeding and/or pelvic pain) diagnosed by ultrasound or magnetic resonance imaging. Data Collection Studies were primarily selected by title and The articles that were eligible for inclusion were evaluated in their entirety, and their data was extracted for further processing and analysis. Data Synthesis From 567 retrieved records only 5 remained for analysis. The intervention groups were: levonorgestrel intrauterine system (LNG-IUS)(n = 2), dienogest (n = 2), and letrozole (n = 1). Levonorgestrel intrauterine system was effective to control bleeding when compared to hysterectomy or combined oral contraceptives (COCs). One study assessed chronic pelvic pain and reported that LNG-IUS was superior to COC to reduce symptoms. Regarding dienogest, it was efficient to reduce pelvic pain when compared to placebo or goserelin, but less effective to control bleeding than gonadotropin-releasing hormone (GnRH) analog. Letrozole was as efficient as GnRH analog to relieve dysmenorrhea and dyspareunia, but not for chronic pelvic pain. Reduction of uterine volume was seen with aromatase inhibitors, GnRH analog, and LGN-IUD. Conclusion Levonorgestrel intrauterine system and dienogest have significantly improved the control of bleeding and pelvic pain, respectively, in women with adenomyosis. However, there is insufficient data from the retrieved studies to endorse each medication for this disease. Further randomized control tests (RCTs) are needed to address pharmacological treatment of adenomyosis.

11 May 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MFMirian Vieira Fraga
Mirian Vieira Fraga
LBLuiz Gustavo Oliveira Brito
Luiz Gustavo Oliveira Brito
DYDaniela Angerame Yela
Daniela Angerame Yela
TMTiciana Alves Mira
Ticiana Alves Mira
CBCristina Laguna Benetti-Pinto
Cristina Laguna Benetti-Pinto

24 February 2020 in Menopause
Verified
Journal Article
Closed access
CBCristina L. Benetti-Pinto
Cristina L. Benetti-Pinto
HGHelena P. Giraldo
Helena P. Giraldo
AGAndrea E. Ms-Vi Giraldo
Andrea E. Ms-Vi Giraldo
TMTiciana A. Ft Mira
Ticiana A. Ft Mira
DYDaniela A. Yela
Daniela A. Yela
Objective: The aim of the study was to evaluate the efficacy of interferential current (IC) in the sexual function of women with premature ovarian insufficiency (POI) using systemic hormone therapy (HT), compared to topical estriol. Methods: A randomized clinical trial with 40 women with POI using systemic HT, who were sexually active and referred for dyspareunia and reduction of lubrication. The women were divided into two treatment groups for 4 weeks: IC group (eight electrotherapy sessions twice a week); or E group (estriol vaginal cream, daily application, 0.5 mg/d). The Female Sexual Function Index was used to evaluate pre-/posttreatment sexual function. Results: Mean age was 37.13 ± 7.27 years and mean treatment time with HT was 8.20 ± 8.73 years, similar data for both groups. There was an improvement in global sexual function, lubrication, and pain domains for both treatments. The differences between the pre-/posttreatment lubrication scores were respectively 0.75 ± 3.31 (P = 0.014) for IC and 1.16 ± 1.22 (P < 0.001) for estriol, whereas for dyspareunia the differences were 1.00 ± 1.47 (P = 0.005) for IC, and 0.68 ± 1.30 (P = 0.006) for estriol. There was no pre-/posttreatment difference for the desire and arousal domains. Only in the IC group did orgasm (difference 0.90 ± 1.42, P = 0.010) and satisfaction improve (difference 0.70 ± 1.28, P = 0.021). Conclusion: The use of perineal IC seems to be a new option for women with POI using systemic HT and presenting with sexual complaints, leading to an improvement in pain, lubrication, satisfaction, and orgasm.